📰 Allogeneic News
Page 5 - Allogeneic News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Allogeneic. Real-time updates on events, politics, business and more.
March 29, 2023
Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or... | March 29, 2023
March 27, 2023
Precision BioSciences, Inc. a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will... | March 27, 2023
February 23, 2023
AlloVir , a late-clinical stage allogeneic T cell immunotherapy company, today announced the appointment of Derek Adams, Ph.D., to its Board of Directors, effective March 1, 2023. Dr. Adams brings... | February 23, 2023
February 16, 2023
- Data presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR - - Analysis of patients receiving meropenem suggest that SYN-004 is well-tolerated with
February 8, 2023
Pierre Fabre to Lead Launch and Commercialization Activities for EBVALLO In Europe Following Transfer of European Commission Marketing Authorization from Atara Biotherapeutics EBVALLO is the
January 11, 2023
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem (invimestrocel) for critical care indications, announced today their participation in two January conferences, Advanced
December 13, 2022
Next-generation Engineering Strategies Designed to Resist Host Immune Cell Rejection Show Enhanced Functionality and Persistence of iPSC-derived Cells in Preclinical Allogeneic ModelsSAN DIEGO, Dec. ... | December 13, 2022
December 11, 2022
Transplanted hypoimmune -modified allogeneic CD19-targeted CAR T cells control CD19+ tumor cells in fully immunocompetent allogeneic humanized mice, evading both the adaptive and innate immune systems... | December 11, 2022
December 10, 2022
Oral podium presentation highlights data demonstrating a 79% overall response rate and complete responses in 43% of relapsed or refractory CD30-positive lymphomas treated with Tessa's "off the shelf" CD30.CAR
November 3, 2022
New data from clinical trials of TT11 and TT11X to be featured in two oral podium presentations and a poster presentationSINGAPORE, Nov. 03, 2022 (Tessa), a clinical-stage cell therapy company developing